Active, not recruitingPhase 1NCT03228537
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
Studying Pleural mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Anne S TsaoSWOG Cancer Research Network
- Intervention
- Atezolizumab(drug)
- Enrollment
- 28 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2026
Study locations (30)
- Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
- CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States
- PCR Oncology, Arroyo Grande, California, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States
- Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States
- AdventHealth Porter, Denver, Colorado, United States
- CommonSpirit Cancer Center Mercy, Durango, Colorado, United States
- Mercy Medical Center, Durango, Colorado, United States
- Mountain Blue Cancer Care Center, Golden, Colorado, United States
- Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, United States
- Saint Anthony Hospital, Lakewood, Colorado, United States
- AdventHealth Littleton, Littleton, Colorado, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03228537 on ClinicalTrials.govOther trials for Pleural mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07192900Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseDavid Bartlett, MD
- RECRUITINGNANCT07126509Partial Pleurectomy (Surgery) for Unresectable Pleural MesotheliomaUniversity of Chicago
- RECRUITINGPHASE1, PHASE2NCT07121374NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility StudyUniversity Hospital, Antwerp
- RECRUITINGPHASE1NCT06885697Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06840834Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyIntergroupe Francophone de Cancerologie Thoracique
- RECRUITINGPHASE2NCT06875076Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural MesotheliomaThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06790082The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural MesotheliomaAalborg University Hospital
- RECRUITINGPHASE1NCT06566079Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid TumorsInSilico Medicine Hong Kong Limited